Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-05-19 Management Reports
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
投资者关系活动记录表
Management Reports Classification · 95% confidence The document is an investor relations activity record from Beijing Sanyuan Gene Pharmaceutical Co., Ltd., dated May 2025. It details a performance explanation meeting (业绩说明会) held over May 15-16, 2025, with extensive Q&A on company operations, R&D progress, financial performance, and strategic initiatives. The content is a detailed discussion of the company's 2024 financial and operational results, including revenue growth, tax changes, cash flow, and product development. This matches the characteristics of a Management Discussion and Analysis (MDA) report, where management explains financial results, business trends, and outlook in detail. It is not a formal Annual Report (10-K) or Interim Report (IR) as it lacks full financial statements and is focused on investor Q&A. It is not a Call Transcript (CT) since it is a written record of an investor meeting, not a conference call transcript. The document length (6655 characters) and detailed content support classification as MDA rather than a brief announcement or presentation. Therefore, the best fit is Management Reports (MDA).
2025-05-19 Chinese
2024年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2024 Annual Report. It references the 2024 Annual Report that was previously disclosed on the Beijing Stock Exchange website. The document provides details about the meeting time, location, participants, and how investors can participate and submit questions. The document length is short (1180 characters) and it does not contain actual financial data or the report itself, but rather announces an event related to the annual report. According to the 'MENU VS MEAL' rule, this is an announcement about a report-related event, not the report itself. Therefore, the appropriate classification is AGM Information (AGM-R), as it is a presentation and materials shared during an annual meeting or similar event explaining the annual report.
2025-05-12 Chinese
申万宏源证券承销保荐有限责任公司关于北京三元基因药业股份有限公向不特定合格投资者公开发行股票之保荐工作总结报告书
Regulatory Filings
2025-05-12 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第一季度报告" which translates to "2025 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and extensive management discussion on business activities and projects. The report explicitly states it is a quarterly report (第一季度报告) and includes financial figures for the period January to March 2025. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-28 Chinese
第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the review and approval of the company's 2025 first quarter report. It includes details about the meeting, voting results, and a statement that the full 2025 first quarter report is disclosed on the Beijing Stock Exchange website. The document itself does not contain the actual financial statements or substantive financial data of the quarterly report but rather the Supervisory Board's review and approval of that report. The document length is short (1200 characters) and it references the full quarterly report being available elsewhere. According to the 'Menu vs Meal' rule, this is an announcement related to the report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement about the review of the quarterly report, not the quarterly report itself.
2025-04-28 Chinese
第四届董事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the fourth board of directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting's time, place, attendees, and the approval of the 2025 first quarter report. However, the actual quarterly report is not included; instead, it references that the report is disclosed on the Beijing Stock Exchange website. The document is primarily a board meeting resolution announcement rather than the quarterly report itself. Given the content and length (997 characters), this fits best as a Regulatory Filing (RNS) because it is an official announcement related to board decisions and report approval but does not contain substantive financial data or the report itself.
2025-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.